<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="19">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 22, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02486406</url>
  </required_header>
  <id_info>
    <org_study_id>M14-748</org_study_id>
    <secondary_id>2015-000111-41</secondary_id>
    <nct_id>NCT02486406</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects</brief_title>
  <acronym>ZIRCON</acronym>
  <official_title>An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Ombitasvir (OBV), Paritaprevir (PTV), Ritonavir (RTV) With or Without Dasabuvir (DSV) and With or Without Ribavirin (RBV) in Pediatric Subjects With Genotype 1 or 4 Chronic Hepatitis C Virus (HCV) Infection (ZIRCON)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this three part study is to evaluate the pharmacokinetics (Part 1),
      safety/efficacy (Part 2), and long-term follow-up (Part 3) of ombitasvir (OBV), paritaprevir
      (PTV), ritonavir (RTV) with or without dasabuvir (DSV) and with or without ribavirin (RBV)
      in pediatric subjects with genotype 1 or 4 chronic hepatitis C virus (HCV) infection.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Part1: Maximum plasma concentration (Cmax) of OBV</measure>
    <time_frame>Pharmacokinetic (PK) samples will be collected at the following timepoints: • Day 1: 4 hours postdose • Week 2: 2, 4, 8, 12 and 24 hours postdose • Week 4: a PK sample • Week 8: a trough PK sample • Week 12: a PK sample</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Maximum plasma concentration (Cmax) of PTV</measure>
    <time_frame>Pharmacokinetic (PK) samples will be collected at the following timepoints: • Day 1: 4 hours postdose • Week 2: 2, 4, 8, 12 and 24 hours postdose • Week 4: a PK sample • Week 8: a trough PK sample • Week 12: a PK sample</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Maximum plasma concentration (Cmax) of DSV</measure>
    <time_frame>Pharmacokinetic (PK) samples will be collected at the following timepoints: • Day 1: 4 hours postdose • Week 2: 2, 4, 8, 12 and 24 hours postdose • Week 4: a PK sample • Week 8: a trough PK sample • Week 12: a PK sample</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Maximum plasma concentration (Cmax) of RTV</measure>
    <time_frame>Pharmacokinetic (PK) samples will be collected at the following timepoints: • Day 1: 4 hours postdose • Week 2: 2, 4, 8, 12 and 24 hours postdose • Week 4: a PK sample • Week 8: a trough PK sample • Week 12: a PK sample</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: concentration of drug in blood plasma against time [Area under the curve (AUC)] of OBV</measure>
    <time_frame>Pharmacokinetic (PK) samples will be collected at the following timepoints: • Day 1: 4 hours postdose • Week 2: 2, 4, 8, 12 and 24 hours postdose • Week 4: a PK sample • Week 8: a trough PK sample • Week 12: a PK sample</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: concentration of drug in blood plasma against time [Area under the curve (AUC)] of PTV</measure>
    <time_frame>Pharmacokinetic (PK) samples will be collected at the following timepoints: • Day 1: 4 hours postdose • Week 2: 2, 4, 8, 12 and 24 hours postdose • Week 4: a PK sample • Week 8: a trough PK sample • Week 12: a PK sample</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: concentration of drug in blood plasma against time [Area under the curve (AUC)] of DSV</measure>
    <time_frame>Pharmacokinetic (PK) samples will be collected at the following timepoints: • Day 1: 4 hours postdose • Week 2: 2, 4, 8, 12 and 24 hours postdose • Week 4: a PK sample • Week 8: a trough PK sample • Week 12: a PK sample</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: concentration of drug in blood plasma against time [Area under the curve (AUC)] of RTV</measure>
    <time_frame>Pharmacokinetic (PK) samples will be collected at the following timepoints: • Day 1: 4 hours postdose • Week 2: 2, 4, 8, 12 and 24 hours postdose • Week 4: a PK sample • Week 8: a trough PK sample • Week 12: a PK sample</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Lowest plasma concentration (Ctrough) of OBV</measure>
    <time_frame>Pharmacokinetic (PK) samples will be collected at the following timepoints: • Day 1: 4 hours postdose • Week 2: 2, 4, 8, 12 and 24 hours postdose • Week 4: a PK sample • Week 8: a trough PK sample • Week 12: a PK sample</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Lowest plasma concentration (Ctrough) of PTV</measure>
    <time_frame>Pharmacokinetic (PK) samples will be collected at the following timepoints: • Day 1: 4 hours postdose • Week 2: 2, 4, 8, 12 and 24 hours postdose • Week 4: a PK sample • Week 8: a trough PK sample • Week 12: a PK sample</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Lowest plasma concentration (Ctrough) of DSV</measure>
    <time_frame>Pharmacokinetic (PK) samples will be collected at the following timepoints: • Day 1: 4 hours postdose • Week 2: 2, 4, 8, 12 and 24 hours postdose • Week 4: a PK sample • Week 8: a trough PK sample • Week 12: a PK sample</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Lowest plasma concentration (Ctrough) of RTV</measure>
    <time_frame>Pharmacokinetic (PK) samples will be collected at the following timepoints: • Day 1: 4 hours postdose • Week 2: 2, 4, 8, 12 and 24 hours postdose • Week 4: a PK sample • Week 8: a trough PK sample • Week 12: a PK sample</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Percentage of treatment-naïve participants with sustained virologic response 24 weeks after the last actual dose of study drug (SVR24)</measure>
    <time_frame>Either 36 weeks or 48 weeks after starting study drug depending on treatment duration (12 or 24 weeks of treatment respectively).</time_frame>
    <safety_issue>No</safety_issue>
    <description>HCV RNA &lt; Lower limit of quantification (LLOQ) 24 weeks after the last actual dose of study drug</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3: Percentage of participants who relapse out of participants who achieved sustained virologic response (SVR) in Part 1 or Part 2 of the study.</measure>
    <time_frame>Any time up to the last follow-up in this study, approximately 4 years.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Relapse is defined as confirmed HCV RNA ≥ LLOQ for a subject with HCV RNA &lt; LLOQ at Final Treatment Visit who completes treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3: Percentage of participants who have new HCV infection</measure>
    <time_frame>Any time up to the last follow-up in this study, approximately 4 years.</time_frame>
    <safety_issue>No</safety_issue>
    <description>The percentage of participants who have new HCV infection at any time up to the last follow-up in this study out of participants who achieved SVR in Part 1 or Part 2.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1: Percentage of participants achieving sustained virologic response 12 weeks after the last actual dose of study drug (SVR12)</measure>
    <time_frame>24 weeks after starting study drug depending on treatment duration.</time_frame>
    <safety_issue>No</safety_issue>
    <description>HCV RNA &lt; LLOQ 12 weeks after the last actual dose of study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Percentage of participants achieving SVR24</measure>
    <time_frame>36 weeks after starting study drug depending on treatment duration.</time_frame>
    <safety_issue>No</safety_issue>
    <description>HCV RNA &lt; LLOQ 24 weeks after the last actual dose of study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Percentage of treatment-naive participants achieving SVR12</measure>
    <time_frame>Either 24 weeks or 36 weeks after starting study drug depending on treatment duration (12 or 24 weeks of treatment respectively).</time_frame>
    <safety_issue>No</safety_issue>
    <description>HCV RNA &lt; LLOQ 12 weeks after the last actual dose of study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Percentage of participants with Alanine aminotransferase (ALT) normalization during treatment</measure>
    <time_frame>During the treatment period (either 12 or 24 weeks)</time_frame>
    <safety_issue>No</safety_issue>
    <description>ALT less than or equal to upper limit of normal (ULN) at the final treatment visit for participants with ALT greater than ULN at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 3: Assess the impact of OBV, PTV, RTV with or without DSV and with or without RBV on height</measure>
    <time_frame>Any time up to the last follow-up in this study, approximately 4 years.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 3: Assess the impact of OBV, PTV, RTV with or without DSV and with or without RBV on waist circumference</measure>
    <time_frame>Any time up to the last follow-up in this study, approximately 4 years.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 3: Assess the impact of OBV, PTV, RTV with or without DSV and with or without RBV on tanner staging</measure>
    <time_frame>Any time up to the last follow-up in this study, approximately 4 years.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">186</enrollment>
  <condition>Chronic Hepatitis C Infection</condition>
  <arm_group>
    <arm_group_label>Genotype 1b, without cirrhosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 weeks of treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Genotype 1a, without cirrhosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 weeks of treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Genotype 1b, with compensated cirrhosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 weeks of treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Genotype 1a, with compensated cirrhosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>24 weeks of treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Genotype 4, without cirrhosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 weeks of treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Genotype 4, with compensated cirrhosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>24 weeks of treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ombitasvir</intervention_name>
    <arm_group_label>Genotype 1b, without cirrhosis</arm_group_label>
    <arm_group_label>Genotype 1a, without cirrhosis</arm_group_label>
    <arm_group_label>Genotype 1b, with compensated cirrhosis</arm_group_label>
    <arm_group_label>Genotype 1a, with compensated cirrhosis</arm_group_label>
    <arm_group_label>Genotype 4, without cirrhosis</arm_group_label>
    <arm_group_label>Genotype 4, with compensated cirrhosis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paritaprevir</intervention_name>
    <arm_group_label>Genotype 1b, without cirrhosis</arm_group_label>
    <arm_group_label>Genotype 1a, without cirrhosis</arm_group_label>
    <arm_group_label>Genotype 1b, with compensated cirrhosis</arm_group_label>
    <arm_group_label>Genotype 1a, with compensated cirrhosis</arm_group_label>
    <arm_group_label>Genotype 4, without cirrhosis</arm_group_label>
    <arm_group_label>Genotype 4, with compensated cirrhosis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ritonavir</intervention_name>
    <arm_group_label>Genotype 1b, without cirrhosis</arm_group_label>
    <arm_group_label>Genotype 1a, without cirrhosis</arm_group_label>
    <arm_group_label>Genotype 1b, with compensated cirrhosis</arm_group_label>
    <arm_group_label>Genotype 1a, with compensated cirrhosis</arm_group_label>
    <arm_group_label>Genotype 4, without cirrhosis</arm_group_label>
    <arm_group_label>Genotype 4, with compensated cirrhosis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dasabuvir</intervention_name>
    <arm_group_label>Genotype 1b, without cirrhosis</arm_group_label>
    <arm_group_label>Genotype 1a, without cirrhosis</arm_group_label>
    <arm_group_label>Genotype 1b, with compensated cirrhosis</arm_group_label>
    <arm_group_label>Genotype 1a, with compensated cirrhosis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ribavirin</intervention_name>
    <arm_group_label>Genotype 1a, without cirrhosis</arm_group_label>
    <arm_group_label>Genotype 1b, with compensated cirrhosis</arm_group_label>
    <arm_group_label>Genotype 1a, with compensated cirrhosis</arm_group_label>
    <arm_group_label>Genotype 4, without cirrhosis</arm_group_label>
    <arm_group_label>Genotype 4, with compensated cirrhosis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Positive anti-HCV Ab and HCV RNA greater than or equal to 1000 IU/mL at the time of
             screening.

          2. HCV genotype 1 for enrollment into Part 1 and genotype 1 or 4 for enrollment into
             Part 2.

          3. Parent or legal guardian with the willingness and ability to provide written informed
             consent and participant willing and able to give assent, as appropriate for age and
             country.

        Exclusion Criteria:

          1. Women who are pregnant or breastfeeding.

          2. Use of known strong inducers and inhibitors (e.g., gemfibrozil) of cytochrome P450
             2C8 (CYP2C8) in participants receiving dasabuvir, or strong or moderate inducers of
             CYP3A, within 2 weeks or 10 half lives, whichever is longer, of the respective
             medication/supplement prior to study drug administration.

          3. Positive test result for Hepatitis B surface antigen (HbsAg) or anti-HIV antibody
             (HIV Ab) test.

          4. Current enrollment in another interventional clinical study, previous enrollment in
             this study, prior or current use of any investigational or commercially available
             anti-HCV agents other than IFNs or RBV or receipt of any investigational product
             within 6 weeks prior to study drug administration.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nancy Shulman, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christopher Negro, MS</last_name>
    <phone>+1 847.935.9357</phone>
    <email>christopher.negro@abbvie.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ulrike Knoop</last_name>
    <phone>+ 49 621 589 1752</phone>
    <email>ulrike.knoop@abbvie.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 136774</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 136774, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 137017</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045-7106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 137017, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 136830</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 136830, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 137015</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 137015, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 136775</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 136775, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 136831</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 136831, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 137174</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 137174</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 136431</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 136431, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 137018</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 137018</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 136590</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 136590, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <lastchanged_date>October 16, 2015</lastchanged_date>
  <firstreceived_date>June 17, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C Genotype 4</keyword>
  <keyword>Pediatric</keyword>
  <keyword>Hepatitis C Genotype 1</keyword>
  <keyword>Hepatitis C Virus</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Ritonavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
